Anivance

Anivance AI is reshaping preclinical research with a fully integrated, animal-free platform aligned with the U.S. FDA's 2025 roadmap for New Approach Methodologies (NAMs). The platform combines organ-on-chip hardware infrastructure (Chip MPS™, ICT Sensing Module™, Aeromimic MPS™), disease models for IPF, Cystic Fibrosis, COPD, Hepatic Fibrosis, and Oncology, and AI-driven decision applications for drug candidate evaluation. Partners include Moderna and Molecular Devices. Founded in 2024 by Dr. Guan-Yu Chen, headquartered at Hsinchu Biotech Park in Taiwan.